Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141858 | 0.91 | SMN1; SMN2 (0.43) | TRPV3TLR7GPR119DPP4DDB1 | |
| SCHEMBL10203527 | 0.88 | DDB1 (0.44) | TRPV3TLR7GPR119DPP4DDB1 | |
| SCHEMBL10179775 | 0.88 | TLR7 (0.39) | TRPV3TLR7GPR119DPP4DDB1 | |
| SCHEMBL10181122 | 0.87 | EGLN1 (0.37) | — | |
| SCHEMBL10179975 | 0.86 | GPR119 (0.47) | TRPV3TLR7GPR119DDB1CRBN | |
| SCHEMBL14142051 | 0.84 | TRPV3 (0.43) | TRPV3TLR7GPR119DPP4SMN1; SMN2 | |
| SCHEMBL10180712 | 0.81 | TLR7 (0.41) | TRPV3TLR7GPR119DDB1CRBN | |
| SCHEMBL10179628 | 0.79 | DDB1 (0.45) | TLR7GPR119DDB1CRBNSMN1; SMN2 | |
| SCHEMBL10180714 | 0.79 | DPP4 (0.48) | TRPV3TLR7GPR119DPP4DDB1 | |
| SCHEMBL14142016 | 0.79 | SMN1; SMN2 (0.40) | TRPV3TLR7GPR119DPP4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | TRPV3 419/4885TLR7 343/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.